Hepatic impairment No dose adjustment is needed in individuals with mild or reasonable (Youngster-Pugh A or B) hepatic impairment (see portion 5.two). Exposure to midostaurin and its Energetic metabolite CGP62221 is significantly reduced in people with serious hepatic impairment than that in patients with ordinary hepatic perform (see part 5. https://franciszekk318bgl2.onzeblog.com/profile